Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2172-2178

  Zeng, Dongfeng ^a   Wang, Jinliang ^a   Kong, Peiyan ^a   Chang, Cheng ^a   Li, Jieping ^a   Li, Jiali ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute leukemia; Angiogenesis; Bone marrow stromal cells; Hypoxia inducible factor 1; Rg3; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; GINSENOSIDE; GINSENOSIDE RG 3; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAPK1 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CELL CULTURE; CHINA; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; STROMA CELL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANGIOGENESIS INHIBITORS; BONE MARROW CELLS; CELLS, CULTURED; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GINSENOSIDES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; STROMAL CELLS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84902520014     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007; 39: 212-220.
2. Di Raimondo F, Palumbo GA, Azzaro MP, Giustolisi R. Angiogenesis in acute myeloid leukemia. Blood 2000; 96: 3656-3657.
3. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
4. Kruizinga RC, de Jonge HJ, Kampen KR, Walenkamp AM, de Bont ES. Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2011; 56: 294-297.
5. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009; 7: 293-302.
6. Dong CG, Wu WK, Feng SY, Yu J, Shao JF, He GM. Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1α. Int J Clin Exp Pathol 2013; 6: 2323-2332.
7. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiol 2009; 24: 97-106.
8. Fang J, Cao Z, Chen YC, Reed E, Jiang BH. 9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Mol Pharmacol 2004; 66: 178-186.
9. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009; 23: 2233-2241.
10. Tsirakis G, Pappa CA, Kanellou P, Stratinaki MA, Xekalou A, Psarakis FE, Sakellaris G, Alegakis A, Stathopoulos EN, Alexandrakis MG. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma. Hematol Oncol 2012; 30: 131-136.
11. Antic D, Jovanovic MP, Fekete MD, Cokic V. Assessment of bone marrow microvessel density in chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol 2010; 18: 353-356.
12. Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008; 143: 622-631.
13. Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 2009; 16: 2924-2942.